Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
211. |
ECCT/21/09/01 | Kuwa Free! - Live free! Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives |
Principal Investigator(s) 1. Rena Patel 2. Edwin Were Site(s) in Kenya Moi Teaching and Referral Hospital |
View |
212. |
ECCT/21/07/01 | RESOLVE A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell DiseaseA Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Jessie Nyokabi Githanga Site(s) in Kenya 1. Strathmore University Medical Center (Nairobi City county) 2. KEMRI Kondele children\'S Hospital (Kisumu county) 3. Gertrude\'s Children\'s Hospital (Nairobi City county) |
View |
213. |
ECCT/21/06/14 | CoVPN 3008 Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Kisumu Clinical Research Site (Kisumu county) |
View |
214. |
ECCT/21/06/13 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) 3. Aga khan University Hospital (Nairobi City county) |
View |
215. |
ECCT/21/07/02 | TALIOS A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |